急性肾损伤的间歇性或连续性肾脏替代治疗
这项多中心、开放标签、非劣效性RCT纳入554例有RRT指征的危重AKI成人,随机分配初始间歇性血透或连续性RRT。因序贯期中分析显示间歇性血透死亡信号持续升高而提前终止。90天主要不良肾脏事件(死亡、RRT依赖或血肌酐超基线25%)间歇组78.1% vs 连续组71.6%(校正绝对风险差6.28个百分点,95%CI -1.22至13.79)。90天死亡63.1% vs 53.5%(HR 1.30,95%CI 1.04-1.63)。结论:间歇性血透未显示非劣于连续性RRT,且与更高死亡率相关。
要点
- 有RRT指征的危重AKI成人,初始间歇性血透90天死亡63.1% vs 连续性RRT 53.5%(HR 1.30,95%CI 1.04-1.63)。
- 主要终点90天主要不良肾脏事件间歇组78.1% vs 连续组71.6%,校正绝对风险差6.28个百分点(95%CI -1.22至13.79),非劣效未成立。
- 试验因序贯期中分析显示间歇性血透死亡率持续更高而提前终止,554例随机、535例纳入意向治疗分析。
- 最常见潜在相关并发症为低血压:间歇组68.8% vs 连续组66.5%。
- 原文结论:间歇性血透作为初始治疗未显示非劣于连续性RRT,且与更高死亡率相关。
适用人群与场景
- 危重成人急性肾损伤且有肾脏替代治疗指征者,纳入随机分配初始间歇性血透或连续性RRT。
诊断标准与关键阈值
- 主要终点主要不良肾脏事件定义:90天内死亡、依赖肾脏替代治疗、或血清肌酐浓度高于基线值25%以上。
- 非劣效性判定:原文未提及非劣效界值。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值。
- 干预为初始治疗方式选择:间歇性血透或连续性肾脏替代治疗,原文未提及具体处方参数。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 多中心、开放标签、非劣效性RCT,554例随机(间歇性血透272例、连续性RRT 282例),535例纳入意向治疗(间歇组260例、连续组275例)。
- 因序贯期中分析显示间歇性血透较连续性RRT死亡率持续更高而提前终止。
- 90天主要不良肾脏事件:间歇组203例(78.1%)vs 连续组197例(71.6%),校正绝对风险差6.28个百分点(95%CI -1.22至13.79)。
- 90天死亡:间歇组164例(63.1%)vs 连续组147例(53.5%);Kaplan-Meier估计63.3% vs 53.6%(HR 1.30,95%CI 1.04-1.63)。
- 最常见潜在与AKI或RRT相关并发症为低血压:间歇组179例(68.8%)vs 连续组183例(66.5%)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、非劣效性随机对照试验(RCT),由法国卫生部资助(ICRAKI,NCT06032884)。
- 局限:开放标签设计;因期中分析显示死亡信号而提前终止,样本量554例;原文未提及其他局限。
对床旁实践的改变
- 对有RRT指征的危重AKI成人,初始选择间歇性血透未证实非劣于连续性RRT,且与更高90天死亡风险相关,支持优先考虑连续性RRT作为初始方式。
- 原文未提及适用或不适用人群的进一步限定,临床决策需结合原文未覆盖的个体情况。
指南或共识出处
- 原文未提及指南或共识出处;研究注册号ICRAKI ClinicalTrials.gov NCT06032884。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The preferred method of renal-replacement therapy for acute kidney injury in critically ill patients remains uncertain.
METHODS: In this multicenter, open-label, noninferiority trial, we randomly assigned critically ill adults with acute kidney injury who had indications for renal-replacement therapy to undergo intermittent hemodialysis or continuous renal-replacement therapy as the initial treatment. The primary outcome was a major adverse kidney event - defined as death, dependence on renal-replacement therapy, or a serum creatinine concentration more than 25% above the baseline value - by day 90.
RESULTS: The trial was stopped early after sequential interim analyses showed a sustained signal of higher mortality with intermittent hemodialysis than with continuous renal-replacement therapy. A total of 554 patients underwent randomization, with 272 patients assigned to undergo intermittent hemodialysis and 282 to undergo continuous renal-replacement therapy; 535 patients (260 in the intermittent group and 275 in the continuous group) were included in the intention-to-treat population. A major adverse kidney event occurred by day 90 in 203 patients (78.1%) in the intermittent group and in 197 patients (71.6%) in the continuous group (adjusted absolute risk difference, 6.28 percentage points; 95% confidence interval [CI], -1.22 to 13.79). Death by day 90 occurred in 164 patients (63.1%) and in 147 patients (53.5%), respectively. Kaplan-Meier mortality estimates at day 90 were 63.3% and 53.6% (hazard ratio, 1.30; 95% CI, 1.04 to 1.63). The most common complication potentially related to acute kidney injury or renal-replacement therapy was hypotension, which occurred in 179 patients (68.8%) in the intermittent group and in 183 patients (66.5%) in the continuous group.
CONCLUSIONS: Among critically ill patients with acute kidney injury who had indications for renal-replacement therapy, intermittent hemodialysis as the initial treatment approach was not shown to be noninferior to continuous renal-replacement therapy with respect to major adverse kidney events by day 90 and was associated with higher mortality. (Funded by the French Ministry of Health; ICRAKI ClinicalTrials.gov number, NCT06032884.).
参考来源
- Gaudry S, Boubaya M, Louis G, et al. Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med. 2026. PMID: 42873070. doi:10.1056/NEJMoa2608397
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。